# PDUFA dates June 2025: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2025-06

> 138 FDA catalysts are dated in June 2025, including 17 PDUFA dates.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What PDUFA dates are in June 2025?

PDUFA dates in June 2025: ENFLONSIA (clesrovimab, MRK) on June 10, 2025; Moderna, Inc. (MRNA) on June 12, 2025; UroGen Pharma Ltd. (URGN) on June 13, 2025; ZUSDURI (mitomycin, URGN) on June 13, 2025; Yeztugo® (lenacapavir, GILD) on June 19, 2025; Sanofi (SNY) on June 20, 2025; and 11 more. [Calendar and source filings](https://sec-api.dev/fda-calendar/2025-06)

Source: SEC Form 10-Q, accession 0001628280-25-021834, https://www.sec.gov/Archives/edgar/data/310158/000162828025021834/mrk-20250331.htm (retrieved 2026-11-12). Last confirmed 2025-05-02. Cite: https://sec-api.dev/fda-calendar/2025-06#answer

## PDUFA dates in June 2025

Data as of November 16, 2026.

| PDUFA date | Company | Ticker | Drug | Indication | Source |
| --- | --- | --- | --- | --- | --- |
| June 10, 2025 | Merck & Co., Inc. | MRK | ENFLONSIA (clesrovimab) |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/310158/000162828025021834/mrk-20250331.htm) |
| June 12, 2025 | Moderna, Inc. | MRNA |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1682852/000168285225000031/exhibit9912025q1pressrelea.htm) |
| June 13, 2025 | UroGen Pharma Ltd. | URGN |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668243/000143774925015955/ex_815371.htm) |
| June 13, 2025 | UroGen Pharma Ltd. | URGN | ZUSDURI (mitomycin) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668243/000143774925015955/ex_815371.htm) |
| June 19, 2025 | GILEAD SCIENCES, INC. | GILD | Yeztugo® (lenacapavir) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209525000009/exhibit991earningspressrel.htm) |
| June 20, 2025 | Sanofi | SNY |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000112140425000013/pressreleaseq12025english.htm) |
| June 20, 2025 | REGENERON PHARMACEUTICALS, INC. | REGN | Dupixent (dupilumab) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000180422025000020/exhibit991q12025.htm) |
| June 23, 2025 | Nuvation Bio Inc. | NUVB | IBTROZI (taletrectinib) | advanced ROS1+ NSCLC | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1811063/000119312525114908/d905090dex991.htm) |
| June 23, 2025 | BIOCRYST PHARMACEUTICALS INC | BCRX | ORLADEYO® (berotralstat) | HAE aged 2 to 11 years due | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/882796/000162828025037795/bcrx-20250630.htm) |
| June 23, 2025 | BRISTOL MYERS SQUIBB CO | BMY |  |  | [SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/bmy-20251231.htm) |
| June 23, 2025 | Merck & Co., Inc. | MRK | cisplatin |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/310158/000162828025021834/mrk-20250331.htm) |
| June 23, 2025 | Nuvation Bio Inc. | NUVB |  |  | [SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1811063/000095017025034903/nuvb-20241231.htm) |
| June 28, 2025 | Unicycive Therapeutics, Inc. | UNCY | UNI-494 |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390025042967/ea024208101ex99-1_unicycive.htm) |
| June 28, 2025 | Unicycive Therapeutics, Inc. | UNCY | oxylanthanum |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390025026270/ea023632401ex99-1_unicycive.htm) |
| June 30, 2025 | NRX Pharmaceuticals, Inc. | NRXP | KETAFREE (ketamine) |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1719406/000143774924035289/nrxp20240930_10q.htm) |
| June 30, 2025 | Verastem, Inc. | VSTM | AVMAPKI (avutometinib) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1526119/000110465925026130/tm259913d1_ex99-1.htm) |
| June 30, 2025 | Verastem, Inc. | VSTM | FAKZYNJA (defactinib) | with KRAS-mutated recurrent LGSOC | [SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1526119/000110465926023444/vstm-20251231x10k.htm) |

## All catalysts in June 2025

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 1, 2025 | [KOMZIFTI (ziftomenib) NDA/BLA acceptance](https://sec-api.dev/pdufa/ziftomenib) | KURA | relapsed or refractory | completed | "On June 1, 2025, Kura Oncology, Inc. (the "Company") and Kyowa Kirin Co., Ltd. ("Kyowa Kirin") announced that the U.S. Food and Drug Administration ("FDA") has accepted the Company's New Drug Application ("NDA") seeking full approval for ziftomenib as a treatment for adult patients with relapsed or refractory ("R/R") acute myeloid leukemia ("AML") with a nucleophosmin 1 ("NPM1") mutation." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1422143/000119312525133717/d917067d8k.htm)) |
| June 1, 2025 | [KOMET-001 NDA/BLA acceptance](https://sec-api.dev/pdufa/komet-001) | KURA |  | completed | "On June 1, 2025, we and Kyowa Kirin announced that the FDA accepted our NDA, granted Priority Review of the NDA and assigned a Prescription Drug User Fee Act, or PDUFA, target action date of November 30, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1422143/000119312525263589/kura-20250930.htm)) |
| June 2025 | [Lp-10 (liposomal tacrolimus) primary completion](https://sec-api.dev/pdufa/lp-10-liposomal-tacrolimus) | LIPO | Oral Lichen Planus | delayed | "NCT06233591 (Evaluating LP-10 in Subjects With OLP): Overall Status UNKNOWN; Phase PHASE2; Primary Completion 2025-06-01 (ESTIMATED); Lead Sponsor Lipella Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06233591)) |
| June 2, 2025 | [Nalbuphine topline data readout](https://sec-api.dev/pdufa/nalbuphine) | TRVI | chronic cough in patients with idiopathic pulmonary fibrosis | completed, positive | "On June 2, 2025, Trevi Therapeutics, Inc., a Delaware corporation (the "Company"), announced positive topline results from its Phase 2b CORAL clinical trial of Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis ("IPF")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1563880/000119312525132890/d949267d8k.htm)) |
| June 2, 2025 | [REGN5381 primary completion](https://sec-api.dev/pdufa/regn5381) | REGN | Heart Failure | completed | "NCT05353166 (REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-02 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals; Results First Posted 2026-09-29." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05353166)) |
| June 2, 2025 | [CERUS CORP primary completion](https://sec-api.dev/companies/cers/catalysts) | CERS | Healthy Subjects | completed | "NCT06697223 (A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated With the INTERCEPT Blood System for Platelets With LED Illuminator.): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-02 (ACTUAL); Lead Sponsor Cerus Corporation; Results First Posted 2026-08-04." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06697223)) |
| June 3, 2025 | [ORZEYFUL (oveporexton) primary completion](https://sec-api.dev/pdufa/oveporexton) | TAK | Narcolepsy Type 1 | completed | "NCT06470828 (A Study of TAK-861 for the Treatment of Narcolepsy Type 1): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-03 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-08-31." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06470828)) |
| June 3, 2025 | [Rsvpref3 oa investigational vaccine primary completion](https://sec-api.dev/pdufa/rsvpref3-oa-investigational-vaccine) | GSK | Respiratory Syncytial Virus Infections | completed | "NCT06614725 (A Study in India on the Immune Response and Safety of a Respiratory Syncytial Virus (RSV) Older Adults (OA) Vaccine When Given to Older Adults 60 Years of Age and Above and Adults 50-59 Years of Age at Increased Risk (AIR) of Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV-LRTD)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-03 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-06-23." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06614725)) |
| June 3, 2025 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-173 (Efficacy): submission_status AP, submission_status_date 20250603, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| June 4, 2025 | [Annamycin topline data readout](https://sec-api.dev/pdufa/annamycin) | MBRX | soft tissue sarcoma lung metastases | completed, positive | "On June 4, 2025, Moleculin Biotech, Inc. (the "Company") issued a press release to announce that it reported positive topline efficacy results from its completed U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases ("STS lung mets") (MB-107)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1659617/000143774925019375/mbrx20250602_8k.htm)) |
| June 4, 2025 | [Barzolvolimab primary completion](https://sec-api.dev/pdufa/barzolvolimab) | CLDX | Eosinophilic Esophagitis | completed | "NCT05774184 (A Study of CDX-0159 in Patients With Eosinophilic Esophagitis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-04 (ACTUAL); Lead Sponsor Celldex Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05774184)) |
| June 4, 2025 | [TAK-861 primary completion](https://sec-api.dev/pdufa/tak-861) | TAK | Narcolepsy Type 1 | completed | "NCT06505031 (A Study of TAK-861 in People With Narcolepsy Type 1): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-04 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-07-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06505031)) |
| June 4, 2025 | [Intervention: as mdi primary completion](https://sec-api.dev/pdufa/intervention-as-mdi) | AZN | Asthma | completed | "NCT06644924 (A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-04 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-08-27." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06644924)) |
| June 5, 2025 | [Vidofludimus topline data readout](https://sec-api.dev/pdufa/vidofludimus) | IMUX |  | completed, positive | "On June 5, 2025, we announced additional data from our Phase 2 CALLIPER trial in PMS, further supporting the positive top-line results announced on April 30, 2025, and underlining vidofludimus calcium's neuroprotective potential." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1280776/000128077625000012/vtl-20250630.htm)) |
| June 5, 2025 | [Paxalisib trial start](https://sec-api.dev/pdufa/paxalisib) | KZIA |  | completed | "Kazia recently announced that the first patient has been dosed in the Phase 1b trial evaluating paxalisib in combination with checkpoint inhibitors and chemotherapy in advanced breast cancer, marking a critical step toward clinical translation of these findings." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1075880/000119312525139172/d116207dex991.htm)) |
| June 5, 2025 | [Soquelitinib interim data readout](https://sec-api.dev/pdufa/soquelitinib) | CRVS |  | scheduled | "Dr. Miller will highlight the new interim data in a presentation at the Jefferies Global Healthcare Conference, which is scheduled for 9:20 am ET / 6:20 am PT on Thursday, June 5, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1626971/000117184325003661/exh_991.htm)) |
| June 5, 2025 | [Irritable bowel syndrome with constipation (ibs-c) participants (lin-md-63 and lin-md-64 completers) primary completion](https://sec-api.dev/pdufa/irritable-bowel-syndrome-with-constipation-ibs-c-participants-lin-md-63-and-lin-) | ABBV | Irritable Bowel Syndrome With Constipation; Functional Constipation | completed | "NCT04166058 (Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-05 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-01-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04166058)) |
| June 5, 2025 | [Cobolimab primary completion](https://sec-api.dev/pdufa/cobolimab) | GSK | Lung Cancer, Non-Small Cell | completed | "NCT04655976 (Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2025-06-05 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-07-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04655976)) |
| June 5, 2025 | [PF-06823859 primary completion](https://sec-api.dev/pdufa/pf-06823859) | PFE | Lupus Erythematosus, Systemic; Lupus Erythematosus, Cutaneous | withdrawn | "NCT05879718 (A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-06-05 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-08-11." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05879718)) |
| June 5, 2025 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Type 2 Diabetes | completed | "NCT06010004 (A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-05 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-06-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06010004)) |
| June 6, 2025 | [VOQUEZNA® (vonoprazan) FDA approval](https://sec-api.dev/pdufa/vonoprazan) | PHAT |  | completed, approved | "As referenced above, on June 6, 2025, the FDA has approved the Citizen Petition and communicated its intention to correct the Orange Book to recognize the proper 10 years of New Chemical Entity exclusivity for VOQUEZNA® (vonoprazan) tablets, extending through May 3, 2032." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1783183/000119312525137094/d941196d8k.htm)) |
| June 6, 2025 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Urinary Bladder Cancer, Muscle-invasive | completed | "NCT03924895 (Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-06-06 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03924895)) |
| June 9, 2025 | [NewAmsterdam Pharma Co N.V. topline data readout](https://sec-api.dev/companies/nams/catalysts) | NAMS |  | completed, positive | "with elevated low-density lipoprotein cholesterol (LDL-C), for whom existing therapies are not sufficiently effective or well-tolerated, today announced positive topline data from prespecified Alzheimers Disease (AD) biomarker analyses in the Phase 3 BROADWAY clinical trial (NCT05142722)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1936258/000119312525137432/d74901dex991.htm)) |
| June 9, 2025 | [Enflonsia (clesrovimab-cfor) FDA approval](https://sec-api.dev/pdufa/clesrovimab-cfor) | MRK |  | completed, approved | "Enflonsia \| clesrovimab-cfor \| 6/9/2025 \| To prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season Drug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| June 9, 2025 | [Paricalcitol primary completion](https://sec-api.dev/pdufa/paricalcitol) | ABBV | Chronic Kidney Disease (CKD); Secondary Hyperparathyroidism (SHPT) | withdrawn | "NCT04064827 (A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-06-09 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-06-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04064827)) |
| June 9, 2025 | [LINZESS® (linaclotide) primary completion](https://sec-api.dev/pdufa/linaclotide) | ABBV | Functional Constipation | completed | "NCT05760313 (A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-09 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-01-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05760313)) |
| June 10, 2025 | [INSMED Inc topline data readout](https://sec-api.dev/companies/insm/catalysts) | INSM | pulmonary arterial hypertension | completed, positive | "On June 10, 2025, the Company announced positive topline results from its Phase 2b TPIP PAH study, a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of TPIP administered once daily in patients with PAH (World Health" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1104506/000114036125022023/ef20050418_8k.htm)) |
| June 10, 2025 | [ENFLONSIA (clesrovimab) PDUFA date](https://sec-api.dev/pdufa/clesrovimab) | MRK |  | scheduled | "In December 2024, the FDA accepted the BLA for clesrovimab and set a PDUFA date of June 10, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/310158/000162828025021834/mrk-20250331.htm)) |
| June 10, 2025 | [Mavyret (glecaprevir; pibrentasvir) label expansion decision](https://sec-api.dev/pdufa/glecaprevir-pibrentasvir) | ABBV |  | completed, approved | "NDA209394 SUPPL-19 (Efficacy): submission_status AP, submission_status_date 20250610, review_priority PRIORITY; sponsor_name ABBVIE; product MAVYRET (GLECAPREVIR; PIBRENTASVIR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209394%22)) |
| June 10, 2025 | [Vudalimab + carboplatin + cabazitaxel primary completion](https://sec-api.dev/pdufa/vudalimab-carboplatin-cabazitaxel) | XNCR | Metastatic Castration-Resistant Prostate Cancer | completed | "NCT05005728 (XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-10 (ACTUAL); Lead Sponsor Xencor, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05005728)) |
| June 10, 2025 | [BRUKINSA® (zanubrutinib) FDA approval](https://sec-api.dev/pdufa/zanubrutinib) | ONC |  | completed, approved | "NDA218785 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20250610, review_priority STANDARD; sponsor_name BEONE MEDICINES USA; product BRUKINSA (ZANUBRUTINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218785%22)) |
| June 11, 2025 | [Vaxart, Inc. topline data readout](https://sec-api.dev/companies/vxrt/catalysts) | VXRT |  | completed, positive | "SOUTH SAN FRANCISCO, Calif., June 11, 2025 — Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today reported positive topline results from the Phase 1 clinical trial evaluating its second-generation oral pill norovirus vaccine constructs head-to-head against its first-generation constructs." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/72444/000143774925020040/ex_829639.htm)) |
| June 11, 2025 | [IBTROZI (taletrectinib) FDA approval](https://sec-api.dev/pdufa/taletrectinib) | NUVB |  | completed, approved | "On June 11, 2025, we announced that the FDA approved IBTROZI (taletrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1+ non-small cell lung cancer (NSCLC)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1811063/000119312525174954/d909051dex991.htm)) |
| June 11, 2025 | [Doxercalciferol (doxercalciferol) label expansion decision](https://sec-api.dev/pdufa/doxercalciferol) | SNY |  | completed, approved | "NDA020862 SUPPL-33 (Efficacy): submission_status AP, submission_status_date 20250611, review_priority STANDARD; sponsor_name SANOFI; product HECTOROL (DOXERCALCIFEROL)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA020862%22)) |
| June 11, 2025 | [Rafael Holdings, Inc. earnings report](https://sec-api.dev/companies/rfl/catalysts) | RFL |  | completed | "- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT), today reported its financial results for the third quarter and first nine months of fiscal year" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1713863/000121390025053266/ea024528601ex99-1_rafael.htm)) |
| June 11, 2025 | [Doxercalciferol (gz427397) primary completion](https://sec-api.dev/pdufa/doxercalciferol-gz427397) | SNY | Secondary Hyperparathyroidism-Chronic Kidney Disease | withdrawn | "NCT02859896 (Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-06-11 (ACTUAL); Lead Sponsor Sanofi; Results First Posted 2026-07-02." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02859896)) |
| June 11, 2025 | [IBTROZI (taletrectinib) primary completion](https://sec-api.dev/pdufa/taletrectinib) | NUVB | Non Small Cell Lung Cancer | completed | "NCT04919811 (Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-06-11 (ACTUAL); Lead Sponsor Nuvation Bio Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04919811)) |
| June 11, 2025 | [Mazisotine primary completion](https://sec-api.dev/pdufa/mazisotine) | LLY | Diabetic Peripheral Neuropathy | completed | "NCT06074562 (A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-11 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-07-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06074562)) |
| June 11, 2025 | [Rsvpref vaccine primary completion](https://sec-api.dev/pdufa/rsvpref-vaccine) | PFE | Respiratory Syncytial Virus | completed | "NCT06325657 (A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-11 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-07-02." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06325657)) |
| June 11, 2025 | [Low dose (ld) rsvt vaccine primary completion](https://sec-api.dev/pdufa/low-dose-ld-rsvt-vaccine) | SNY | RSV Immunisation; Healthy Volunteers | withdrawn | "NCT06705140 (A Study on the Immunogenicity and Safety of 3 Different Dose Concentrations of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-06-11 (ACTUAL); Lead Sponsor Sanofi Pasteur, a Sanofi Company; Results First Posted 2026-08-03." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06705140)) |
| June 11, 2025 | [Ibtrozi (taletrectinib adipate) FDA approval](https://sec-api.dev/pdufa/taletrectinib-adipate) | NUVB | To treat locally advanced or metastatic ROS1-positive non-small cell lung cancer | completed, approved | "Ibtrozi \| taletrectinib \| 6/11/2025 \| To treat locally advanced or metastatic ROS1-positive non-small cell lung cancerDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| June 12, 2025 | [Moderna, Inc. PDUFA date](https://sec-api.dev/companies/mrna/catalysts) | MRNA |  | scheduled | "The FDA has assigned a PDUFA goal date of June 12, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1682852/000168285225000031/exhibit9912025q1pressrelea.htm)) |
| June 12, 2025 | [EnGene Therapeutics Inc. earnings report](https://sec-api.dev/companies/engn/catalysts) | ENGN |  | completed | "EX-99.1 enGene Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1980845/000095017025085138/engn-ex99_1.htm)) |
| June 12, 2025 | [ZUSDURI (mitomycin) FDA approval](https://sec-api.dev/pdufa/mitomycin) | URGN | with recurrent low-grade intermediate risk NMIBC | completed, approved | "ZUSDURI was approved by the U.S. Food and Drug Administration (FDA) on June 12, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668243/000143774926006233/ex_925621.htm)) |
| June 12, 2025 | [Zepbound (tirzepatide) primary completion](https://sec-api.dev/pdufa/tirzepatide) | LLY | Type 2 Diabetes Mellitus | completed | "NCT04255433 (A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-12 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-07-08." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04255433)) |
| June 12, 2025 | [Talzenna (talazoparib tosylate) label expansion decision](https://sec-api.dev/pdufa/talazoparib) | PFE |  | completed, approved | "NDA217439 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20250612, review_priority PRIORITY; sponsor_name PFIZER; product TALZENNA (TALAZOPARIB TOSYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217439%22)) |
| June 13, 2025 | [CARDAMYST (etripamil) NDA/BLA acceptance](https://sec-api.dev/pdufa/etripamil) | MIST |  | completed | "On June 13, 2025, we submitted our response to the FDA's CRL regarding the NDA for CARDAMYST (etripamil) nasal spray, which was accepted." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1408443/000155837025011141/mist-20250630x10q.htm)) |
| June 13, 2025 | [UroGen Pharma Ltd. PDUFA date](https://sec-api.dev/companies/urgn/catalysts) | URGN |  | scheduled | "The FDA granted a Prescription Drug User Fee Act (PDUFA) target action date of June 13, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668243/000143774925015955/ex_815371.htm)) |
| June 13, 2025 | [ZUSDURI (mitomycin) PDUFA date](https://sec-api.dev/pdufa/mitomycin) | URGN |  | completed, approved | "New Drug Application for UGN-102 on track for FDA-PDUFA target action date of June 13, 2025; assuming approval, commercial launch to immediately follow with product availability in July" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668243/000143774925015955/ex_815371.htm)) |
| June 13, 2025 | [CARDAMYST (etripamil) NDA/BLA submission](https://sec-api.dev/pdufa/etripamil) | MIST |  | completed | "On June 13, 2025, we submitted our response to the FDA's CRL regarding the NDA for CARDAMYST (etripamil) nasal spray." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1408443/000155837025011141/mist-20250630x10q.htm)) |
| June 13, 2025 | [Tybost (cobicistat) primary completion](https://sec-api.dev/pdufa/cobicistat) | GILD | Acquired Immune Deficiency Syndrome (AIDS); HIV Infections | completed | "NCT02016924 (Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2025-06-13 (ACTUAL); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02016924)) |
| June 13, 2025 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Advanced Non-Small Cell Lung Cancer | completed | "NCT03516981 (A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-13 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-08." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03516981)) |
| June 16, 2025 | [Anaphylm™ (dibutepinephrine) NDA/BLA acceptance](https://sec-api.dev/pdufa/dibutepinephrine) | AQST | Type 1 allergic reactions | completed | "FDA assigns PDUFA target action date of January 31, 2026 WARREN, N.J., June 16, 2025 - Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for Anaphylm™ in the treatment of Type 1 allergic reactions, including anaphylaxis, and has assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000162828025031455/prndaacceptancedraft6-13.htm)) |
| June 16, 2025 | [Aldeyra Therapeutics, Inc. NDA/BLA acceptance](https://sec-api.dev/companies/aldx/catalysts) | ALDX |  | completed | "Following submission on June 16, 2025, the NDA was accepted for review as a "complete class 2 response" by the FDA on July 16, 2025, with a target PDUFA action date of December 16, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1341235/000119312525319638/aldx-ex99_1.htm)) |
| June 16, 2025 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Non-Muscle- Invasive Bladder Cancer | completed | "NCT05943106 (BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-06-16 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05943106)) |
| June 17, 2025 | [Lorundrostat topline data readout](https://sec-api.dev/pdufa/lorundrostat) | MLYS |  | completed, positive | "On June 17, 2025, the Company announced positive topline data from its Phase 2 Explore-CKD trial evaluating the safety and efficacy of 25 mg of lorundrostat in subjects with hypertension and comorbid CKD." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1933414/000193341425000070/mlys-20250617.htm)) |
| June 17, 2025 | [Vistagen Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vtgn/catalysts) | VTGN |  | completed | "Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1411685/000141168525000046/vtgn-20250612xex991_final.htm)) |
| June 17, 2025 | [Fludarabine primary completion](https://sec-api.dev/pdufa/fludarabine) | GILD | Relapsed/Refractory Mantle Cell Lymphoma | completed | "NCT04880434 (Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-17 (ACTUAL); Lead Sponsor Kite, A Gilead Company; Results First Posted 2026-08-18." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04880434)) |
| June 17, 2025 | [Alcestobart primary completion](https://sec-api.dev/pdufa/alcestobart) | ONC | Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer | completed | "NCT05909904 (A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-17 (ACTUAL); Lead Sponsor BeiGene; Results First Posted 2026-07-14." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05909904)) |
| June 18, 2025 | [ISEMBYLD (apitegromab) topline data readout](https://sec-api.dev/pdufa/apitegromab) | SRRK | obesity receiving tirzepatide | completed, positive | "On June 18, 2025, we announced positive top-line data from our Phase 2 EMBRAZE clinical trial evaluating apitegromab, an investigational muscle-targeted treatment, with tirzepatide to preserve lean mass during tirzepatide-induced weight loss." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1727196/000155837025010400/srrk-20250630x10q.htm)) |
| June 18, 2025 | [Dupixent (dupilumab) label expansion decision](https://sec-api.dev/pdufa/dupilumab) | REGN |  | completed, approved | "BLA761055 SUPPL-70 (Efficacy): submission_status AP, submission_status_date 20250618, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22)) |
| June 18, 2025 | [Yeztugo® (lenacapavir) FDA approval](https://sec-api.dev/pdufa/lenacapavir) | GILD |  | completed, approved | "NDA220020 ORIG-1 (Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated): submission_status AP, submission_status_date 20250618, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product YEZTUGO (LENACAPAVIR SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA220020%22)) |
| June 18, 2025 | [Yeztugo (lenacapavir; lenacapavir sodium) FDA approval](https://sec-api.dev/pdufa/lenacapavir-lenacapavir) | GILD |  | completed, approved | "NDA220018 ORIG-1 (Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated): submission_status AP, submission_status_date 20250618, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product YEZTUGO (LENACAPAVIR; LENACAPAVIR SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA220018%22)) |
| June 18, 2025 | [Deramiocel primary completion](https://sec-api.dev/pdufa/deramiocel) | CAPR | Muscular Dystrophies; Muscular Dystrophy, Duchenne; Muscular Disorders, Atrophic | completed | "NCT05126758 (A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-06-18 (ACTUAL); Lead Sponsor Capricor Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05126758)) |
| June 18, 2025 | [SAR441566 primary completion](https://sec-api.dev/pdufa/sar441566) | SNY | Rheumatoid Arthritis | completed | "NCT06073093 (A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-18 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06073093)) |
| June 18, 2025 | [ADX-629 primary completion](https://sec-api.dev/pdufa/adx-629) | ALDX | Alcohol Hepatitis | completed | "NCT06685692 (A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-18 (ACTUAL); Lead Sponsor Aldeyra Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06685692)) |
| June 18, 2025 | [ZEJULA (niraparib) label expansion decision](https://sec-api.dev/pdufa/niraparib) | GSK |  | completed, approved | "NDA214876 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20250618, review_priority STANDARD; sponsor_name GLAXOSMITHKLINE; product ZEJULA (NIRAPARIB TOSYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214876%22)) |
| June 19, 2025 | [Yeztugo® (lenacapavir) PDUFA date](https://sec-api.dev/pdufa/lenacapavir) | GILD |  | completed, approved | "•Announced FDA accepted New Drug Application submissions for twice-yearly lenacapavir for HIV prevention under priority review, with a PDUFA date of June 19, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209525000009/exhibit991earningspressrel.htm)) |
| June 19, 2025 | [Ianalumab primary completion](https://sec-api.dev/pdufa/ianalumab) | NVS | Primary Immune Thrombocytopenia | completed | "NCT05653219 (A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-06-19 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05653219)) |
| June 19, 2025 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Obesity | completed | "NCT05931380 (A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-19 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-07-20." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05931380)) |
| June 19, 2025 | [Zilebesiran primary completion](https://sec-api.dev/pdufa/zilebesiran) | ALNY | High Cardiovascular Risk; Hypertension | completed | "NCT06272487 (Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-19 (ACTUAL); Lead Sponsor Alnylam Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06272487)) |
| June 19, 2025 | [Alks 2680 dose 1 primary completion](https://sec-api.dev/pdufa/alks-2680) | ALKS | Narcolepsy Type 1 | completed | "NCT06358950 (A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-19 (ACTUAL); Lead Sponsor Alkermes, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06358950)) |
| June 20, 2025 | [Sanofi PDUFA date](https://sec-api.dev/companies/sny/catalysts) | SNY |  | scheduled | "The target action date for the FDA decision is June 20, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000112140425000013/pressreleaseq12025english.htm)) |
| June 20, 2025 | [Dupixent (dupilumab) PDUFA date](https://sec-api.dev/pdufa/dupilumab) | REGN |  | completed, approved | "In February 2025, the FDA accepted for priority review the supplemental Biologics License Application (sBLA) for Dupixent in bullous pemphigoid, with a target action date of June 20, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000180422025000020/exhibit991q12025.htm)) |
| June 20, 2025 | [Benlysta (belimumab) label expansion decision](https://sec-api.dev/pdufa/belimumab) | GSK |  | completed, approved | "BLA761043 SUPPL-34 (Efficacy): submission_status AP, submission_status_date 20250620, review_priority STANDARD; sponsor_name GLAXOSMITHKLINE LLC; product BENLYSTA (BELIMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761043%22)) |
| June 20, 2025 | [Tybost (cobicistat) label expansion decision](https://sec-api.dev/pdufa/cobicistat) | GILD |  | completed, approved | "NDA203094 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20250620, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product TYBOST (COBICISTAT)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA203094%22)) |
| June 20, 2025 | [Descovy (emtricitabine; tenofovir alafenamide fumarate) label expansion decision](https://sec-api.dev/pdufa/emtricitabine-tenofovir-alafenamide) | GILD |  | completed, approved | "NDA208215 SUPPL-25 (Efficacy): submission_status AP, submission_status_date 20250620, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product DESCOVY (EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208215%22)) |
| June 20, 2025 | [Bemarituzumab primary completion](https://sec-api.dev/pdufa/bemarituzumab) | AMGN | Gastric Cancer; Gastroesophageal Junction Adenocarcinoma | completed | "NCT05052801 (Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-20 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05052801)) |
| June 23, 2025 | [IBTROZI (taletrectinib) PDUFA date](https://sec-api.dev/pdufa/taletrectinib) | NUVB | advanced ROS1+ NSCLC | completed, approved | "The PDUFA goal date of June 23, 2025 positions Nuvation Bio to commercialize taletrectinib in the U.S., if approved, in mid-2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1811063/000119312525114908/d905090dex991.htm)) |
| June 23, 2025 | [ORLADEYO® (berotralstat) PDUFA date](https://sec-api.dev/pdufa/berotralstat) | BCRX | HAE aged 2 to 11 years due | scheduled | "On June 23, 2025, the FDA extended the PDUFA goal date for our NDA for the use of once-daily ORLADEYO oral granules in pediatric patients with HAE aged 2 to 11 years due to our submission of additional final reports and formulation data, which resulted in a standard three-month extension to the original goal date to provide time for a full review of the submission." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/882796/000162828025037795/bcrx-20250630.htm)) |
| June 23, 2025 | [Grace Therapeutics, Inc. earnings report](https://sec-api.dev/companies/grce/catalysts) | GRCE |  | completed | "Grace Therapeutics Announces 2025 Fiscal Year-End Results," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036125023261/ef20050698_ex99-1.htm)) |
| June 23, 2025 | [BRISTOL MYERS SQUIBB CO PDUFA date](https://sec-api.dev/companies/bmy/catalysts) | BMY |  | scheduled | "This approval, granted more than two months ahead of the June 23, 2025 PDUFA goal date, follows the FDA's prior decision to grant the application Breakthrough Therapy Designation and Priority Review status." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/bmy-20251231.htm)) |
| June 23, 2025 | [Cisplatin PDUFA date](https://sec-api.dev/pdufa/cisplatin) | MRK |  | scheduled | "The FDA set a PDUFA date of June 23, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/310158/000162828025021834/mrk-20250331.htm)) |
| June 23, 2025 | [Nuvation Bio Inc. PDUFA date](https://sec-api.dev/companies/nuvb/catalysts) | NUVB |  | scheduled | "NDA with Priority Review designation and assigned a PDUFA target action date of June 23, 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1811063/000095017025034903/nuvb-20241231.htm)) |
| June 23, 2025 | [Neuraceq (florbetaben f-18) label expansion decision](https://sec-api.dev/pdufa/florbetaben-f-18) | LNTH |  | completed, approved | "NDA204677 SUPPL-24 (Efficacy): submission_status AP, submission_status_date 20250623, review_priority UNKNOWN; sponsor_name LANTHEUS; product NEURACEQ (FLORBETABEN F-18)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204677%22)) |
| June 23, 2025 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Small Cell Lung Cancer | completed | "NCT04924101 (Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-23 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-07-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04924101)) |
| June 23, 2025 | [EDP-938 primary completion](https://sec-api.dev/pdufa/edp-938) | ENTA | RSV Infection | completed | "NCT05568706 (A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-23 (ACTUAL); Lead Sponsor Enanta Pharmaceuticals, Inc; Results First Posted 2026-08-19." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05568706)) |
| June 24, 2025 | [Isaralgagene civaparvovec topline data readout](https://sec-api.dev/pdufa/isaralgagene-civaparvovec) | SGMOQ | with Fabry disease | completed, positive | "On June 24, 2025, Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") announced positive topline results from the registrational Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned investigational gene therapy for the treatment of adults with Fabry disease." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1001233/000162828025032748/sgmo-20250624.htm)) |
| June 24, 2025 | [Journey Medical Corp FDA approval](https://sec-api.dev/companies/derm/catalysts) | DERM | dermatological conditions, today | completed, approved | "Corporation (Nasdaq: DERM) ("Journey Medical" or the "Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company will join the small-cap" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867066/000110465925061956/tm2518699d1_ex99-1.htm)) |
| June 24, 2025 | [Obefazimod primary completion](https://sec-api.dev/pdufa/obefazimod) | ABVX | Ulcerative Colitis | completed | "NCT05507203 (ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-24 (ACTUAL); Lead Sponsor Abivax S.A.; Results First Posted 2026-09-10." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05507203)) |
| June 24, 2025 | [Obefazimod primary completion](https://sec-api.dev/pdufa/obefazimod) | ABVX | Ulcerative Colitis | completed | "NCT05507216 (ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-24 (ACTUAL); Lead Sponsor Abivax S.A.; Results First Posted 2026-09-10." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05507216)) |
| June 24, 2025 | [VK2735 primary completion](https://sec-api.dev/pdufa/vk2735) | VKTX | Weight Loss | completed | "NCT06828055 (VK2735 for Weight Management Phase 2 (Venture Oral Dosing)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-24 (ACTUAL); Lead Sponsor Viking Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06828055)) |
| June 25, 2025 | [Alvotech topline data readout](https://sec-api.dev/companies/alvo/catalysts) | ALVO |  | completed, positive | "On 25 June 2025, the Company announced the positive topline results from a confirmatory efficacy study comparing AVT23 with the reference biologic." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000189841625000009/alvo-20250630.htm)) |
| June 25, 2025 | [Efzofitimod primary completion](https://sec-api.dev/pdufa/efzofitimod) | ATYR | Pulmonary Sarcoidosis | completed | "NCT05415137 (Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-25 (ACTUAL); Lead Sponsor aTyr Pharma, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05415137)) |
| June 25, 2025 | [Emraclidine primary completion](https://sec-api.dev/pdufa/emraclidine) | ABBV | Schizophrenia | withdrawn | "NCT05443724 (A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-06-25 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-08-21." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05443724)) |
| June 26, 2025 | [Lipocine Inc. trial start](https://sec-api.dev/companies/lpcn/catalysts) | LPCN |  | completed | "Press Release announcing Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1535955/000164117225016589/form8-k.htm)) |
| June 26, 2025 | [Pemvidutide topline data readout](https://sec-api.dev/pdufa/pemvidutide) | ALT |  | completed, positive | "GAITHERSBURG, MD, - June 26, 2025 - Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced positive topline results from the IMPACT Phase 2b trial in metabolic dysfunction-associated steatohepatitis (MASH)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326190/000132619025000037/alt-20250626xex99d1.htm)) |
| June 26, 2025 | [Opus Genetics, Inc. topline data readout](https://sec-api.dev/companies/ird/catalysts) | IRD | inherited retinal diseases | completed, positive | "Research Triangle Park, NC June 26, 2025 - Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced positive topline results from VEGA-3, its second pivotal Phase 3 trial evaluating Phentolamine Ophthalmic Solution" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1228627/000114036125023732/ef20051231_ex99-1.htm)) |
| June 26, 2025 | [Lipocine Inc. trial start](https://sec-api.dev/companies/lpcn/catalysts) | LPCN |  | completed | "LAKE CITY, June 26, 2025 — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced that the first patient has been dosed in its pivotal Phase" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1535955/000164117225016589/ex99-1.htm)) |
| June 26, 2025 | [Earth Science Tech, Inc. earnings report](https://sec-api.dev/companies/etst/catalysts) | ETST |  | completed | "Science Tech, Inc. Reports Fiscal Year-End Results for March 31, 2025, with Revenue Exceeding $33.1 Million and Net Profit of $3.2 Million" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1538495/000164117225016721/ex99-1.htm)) |
| June 26, 2025 | [Sapablursen primary completion](https://sec-api.dev/pdufa/sapablursen) | IONS | Phlebotomy Dependent Polycythemia Vera | completed | "NCT05143957 (A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-26 (ACTUAL); Lead Sponsor Ionis Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05143957)) |
| June 27, 2025 | [KLU156 primary completion](https://sec-api.dev/pdufa/klu156) | NVS | Uncomplicated Plasmodium Falciparum Malaria | completed | "NCT05842954 (Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-27 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals; Results First Posted 2026-11-04." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05842954)) |
| June 27, 2025 | [MRNA-1345 primary completion](https://sec-api.dev/pdufa/mrna-1345) | MRNA | Respiratory Syncytial Virus | completed | "NCT06097299 (A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-27 (ACTUAL); Lead Sponsor ModernaTX, Inc.; Results First Posted 2026-08-18." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06097299)) |
| June 27, 2025 | [Efinopegdutide primary completion](https://sec-api.dev/pdufa/efinopegdutide) | MRK |  | completed | "NCT06482112 (Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-27 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06482112)) |
| June 27, 2025 | [Nda218607 complete response letter (CRL)](https://sec-api.dev/pdufa/nda218607) | UNCY |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA218607_20250627.pdf%22)) |
| June 28, 2025 | [UNI-494 PDUFA date](https://sec-api.dev/pdufa/uni-494) | UNCY |  | scheduled | "The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2025, for OLC." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390025042967/ea024208101ex99-1_unicycive.htm)) |
| June 28, 2025 | [Oxylanthanum PDUFA date](https://sec-api.dev/pdufa/oxylanthanum) | UNCY |  | completed, complete response letter | "- Oxylanthanum carbonate (OLC) New Drug Application for hyperphosphatemia in chronic kidney disease patients on dialysis under review by the FDA with a PDUFA target action date of June 28, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390025026270/ea023632401ex99-1_unicycive.htm)) |
| June 29, 2025 | [Btos-ha primary completion](https://sec-api.dev/pdufa/btos-ha) | BLCO | Ocular Redness | completed | "NCT06803654 (A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular Redness): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-29 (ACTUAL); Lead Sponsor Bausch & Lomb Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06803654)) |
| June 30, 2025 | [RYTELO (imetelstat) FDA approval](https://sec-api.dev/pdufa/imetelstat) | GERN |  | completed, approved | "Total product revenue, net for the three and six months ended June 30, 2025, was $49.0 million and $88.4 million, compared to $780,000 for the three and six months ended June 30, 2024, as RYTELO was approved by the FDA in June 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886744/000088674425000048/gern-20250630xexx991.htm)) |
| June 30, 2025 | [Ryoncil (ryoncil) FDA approval](https://sec-api.dev/pdufa/ryoncil) | MESO | SR-aGVHD in December 2024 | completed, approved | "Selling, marketing and distribution increased by $11.4 million from $4.7 million for the year ended June 30, 2025 to $16.1 million for the year ended June 30, 2026 primarily due to increased commercial activities for Ryoncil® following FDA approval of the product for the treatment of pediatric SR-aGVHD in December 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1345099/000134509926000087/exhibit991annualreportag.htm)) |
| June 30, 2025 | [Tonix Pharmaceuticals Holding Corp. NDA/BLA acceptance](https://sec-api.dev/companies/tnxp/catalysts) | TNXP |  | completed | "During the six months ended June 30, 2025, warrants totaling 13,666 became exercisable, 5,758 became exercisable upon FDA acceptance of our NDA filing, and 1, with an exercise price of $1,056, $1,776 and $364,800, respectively, expired." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1430306/000199937126017452/tnxp-10q_063026.htm)) |
| June 30, 2025 | [Spikevax (spikevax) FDA approval](https://sec-api.dev/pdufa/spikevax) | MRNA |  | completed, approved | "As of June 30, 2025, we have three commercial products, our COVID vaccines, Spikevax and mNEXSPIKE, and our RSV vaccine, mRESVIA. mRESVIA was approved by the FDA in May 2024 for adults aged 60 years and older, and in June 2025, the approved use was expanded to include adults aged 18 through 59 years who are at increased risk for RSV disease." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1682852/000168285225000044/mrna-20250630.htm)) |
| June 30, 2025 | [BRIUMVI® (ublituximab) FDA approval](https://sec-api.dev/pdufa/ublituximab) | TGTX |  | completed, approved | "At June 30, 2025, our inventory was solely related to BRIUMVI, which was approved by the FDA in December 2022, at which time we began to capitalize costs to manufacture BRIUMVI." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1001316/000143774925025745/tgtx20250630_10q.htm)) |
| June 30, 2025 | [Deficiency interim data readout](https://sec-api.dev/pdufa/deficiency) | ARCT |  | completed, positive | "On June 30, 2025, we announced positive multiple dosing data of ARCT-810 from two Phase 2 studies: (i) a completed placebo-controlled study in Europe that randomized eight participants to ARCT-810 0.3 mg/kg or placebo; and (ii) an open-label multiple ascending dose study in the U.S., with interim data from the initial three completed participants." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1768224/000119312526088391/arct-20251231.htm)) |
| June 30, 2025 | [KETAFREE (ketamine) PDUFA date](https://sec-api.dev/pdufa/ketamine) | NRXP |  | scheduled | "The anticipated PDUFA date for this settlement is prior to June 30, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1719406/000143774924035289/nrxp20240930_10q.htm)) |
| June 30, 2025 | [Cancer trial start](https://sec-api.dev/pdufa/cancer) | TYRA |  | completed | "On June 30, 2025, Tyra Biosciences, Inc. (Tyra or the Company) announced the first patient has been dosed in the SURF302 Phase 2 clinical study of TYRA-300 in low-grade, intermediate risk non-muscle invasive bladder cancer (IR NMIBC)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1863127/000119312525152016/d11524d8k.htm)) |
| June 30, 2025 | [AVMAPKI (avutometinib) PDUFA date](https://sec-api.dev/pdufa/avutometinib) | VSTM |  | completed, approved | "Avutometinib and Defactinib in Recurrent Low - Grade Serous Ovarian Cancer (LGSOC) PDUFA Action Date: June 30, 2025 Potential Launch in KRAS mutant Recurrent LGSOC in mid - 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1526119/000110465925026130/tm259913d1_ex99-1.htm)) |
| June 30, 2025 | [KAMADA LTD FDA approval](https://sec-api.dev/companies/kmda/catalysts) | KMDA |  | completed, approved | "Announced that the U.S. Food and Drug Administration (FDA) has approved the supplement to the Company's existing Biologics License Application (BLA) for its collection center in Houston," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1567529/000121390025075264/ea025079101ex99-1_kamada.htm)) |
| June 30, 2025 | [Selonabant trial start](https://sec-api.dev/pdufa/selonabant) | ANEB |  | completed | "We incurred increased pre-clinical and clinical studies and contract manufacturing expenses in the year ended June 30, 2025 as we began to prepare for our Phase 1 SAD study for IV selonabant." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815974/000149315225016001/ex99-1.htm)) |
| June 30, 2025 | [Oxylanthanum complete response letter (CRL)](https://sec-api.dev/pdufa/oxylanthanum) | UNCY | Hyperphosphatemia in Patients with Chronic Kidney Disease | completed, complete response letter | "Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390025059303/ea024746901ex99-1_unicycive.htm)) |
| June 30, 2025 | [Coya Therapeutics, Inc. NDA/BLA submission](https://sec-api.dev/companies/coya/catalysts) | COYA |  | completed | "On June 30, 2025, the Company re-submitted the Investigational New Drug Application (the "IND") that includes the requested data to the FDA." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1835022/000119312525153465/d17294d8k.htm)) |
| June 30, 2025 | [Felzartamab trial start](https://sec-api.dev/pdufa/felzartamab) | BIIB | IgAN | completed | "During the first quarter of 2025 we accrued a milestone payment due to MorphoSys of $35.0 million upon the first patient dosed in a Phase 3 clinical trial of felzartamab for the treatment of AMR, which was recorded within acquired in-process research and development, upfront and milestone expense in our condensed consolidated statements of income for the six months ended June 30, 2025, and subsequently paid in April 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/875045/000087504525000033/biib-20250630.htm)) |
| June 30, 2025 | [Revuforj® (revumenib) NDA/BLA submission](https://sec-api.dev/pdufa/revumenib) | SNDX |  | completed | "In the three months ended June 30, 2025 the Company the submitted an supplemental New Drug Application (sNDA) to the U.S. FDA for a second indication for Revuforj." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1395937/000095017025101985/sndx-20250630.htm)) |
| June 30, 2025 | [FAKZYNJA (defactinib) PDUFA date](https://sec-api.dev/pdufa/defactinib) | VSTM | with KRAS-mutated recurrent LGSOC | scheduled | "AVMAPKI FAKZYNJA CO-PACK received accelerated approval by the U.S. Food and Drug Administration (FDA) on May 8, 2025 for the treatment of adults with KRAS-mutated recurrent LGSOC who have received prior systemic therapy, approximately two months in advance of the Prescription Drug User Fee Act ("PDUFA") action date of June 30, 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1526119/000110465926023444/vstm-20251231x10k.htm)) |
| June 30, 2025 | [Protocol FDA approval](https://sec-api.dev/pdufa/protocol) | AIM |  | completed, approved | "For the three months ended June 30, 2025 and 2024, we had no Alferon N Injection® Finished Good product to commercially sell and all revenue was generated from the EAP and our FDA approved open-label treatment protocol, ("AMP 511"), that allows patient access to Ampligen® for treatment in an open-label safety study." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/946644/000149315225011986/form10-q.htm)) |
| June 30, 2025 | [NuCana plc trial start](https://sec-api.dev/companies/ncna/catalysts) | NCNA | PD-1 inhibitor-resistant melanoma," said Andrew Kay, NuCana's Executive Chairman | completed | ""We are pleased to announce that the first patients have been dosed on the expansion of our ongoing Phase 1/2 NuTide:701 study in patients with PD-1 inhibitor-resistant melanoma," said Andrew Kay, NuCana's Executive Chairman." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1709626/000119312525184104/d88837dex993.htm)) |
| June 30, 2025 | [Sanofi FDA approval](https://sec-api.dev/companies/sny/catalysts) | SNY |  | completed, approved | "Sanofi's collaboration partner Novavax, Inc. announced that the US FDA had approved the biologics license application ("BLA) for Nuvaxovid for active immunization to prevent coronavirus disease 2019 ("COVID-19") caused by severe acute respiratory syndrome coronavirus 2 ("SARS-CoV-2") in adults aged 65 years and older and individuals aged 12 through 64 years who have at least one underlying condition that puts them at high risk for severe outcomes from COVID-19 (e.g. asthma, cancer, diabetes, obesity, smoking)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000119312525250744/d69958dex992.htm)) |
| June 30, 2025 | [ELITE PHARMACEUTICALS INC /NV/ earnings report](https://sec-api.dev/companies/eltp/catalysts) | ELTP |  | completed | "Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2025 and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053369/000164117225017151/ex99-1.htm)) |
| June 30, 2025 | [CUE-101 trial start](https://sec-api.dev/pdufa/cue-101) | CUE |  | completed | "As of June 30, 2025, two of these milestones had been achieved, as we had filed an IND application in 2019, and initiated the investigator sponsored Phase 1b neoadjuvant clinical trial for CUE-101 in 2021." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1645460/000095017025107270/cue-20250630.htm)) |
| June 30, 2025 | [AZD9833 primary completion](https://sec-api.dev/pdufa/azd9833) | AZN | ER-Positive HER2-Negative Breast Cancer | completed | "NCT04964934 (Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-06-30 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04964934)) |
| June 30, 2025 | [REC-994 primary completion](https://sec-api.dev/pdufa/rec-994) | RXRX | Cerebral Cavernous Malformation | completed | "NCT05085561 (The Symptomatic Cerebral Cavernous Malformation Trial of REC-994): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-30 (ACTUAL); Lead Sponsor Recursion Pharmaceuticals Inc.; Results First Posted 2026-10-22." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05085561)) |
| June 30, 2025 | [Inhaled treprostinil primary completion](https://sec-api.dev/pdufa/inhaled-treprostinil) | UTHR | Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease | completed | "NCT05255991 (Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-30 (ACTUAL); Lead Sponsor United Therapeutics; Results First Posted 2026-10-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05255991)) |
| June 30, 2025 | [Dialysis primary completion](https://sec-api.dev/pdufa/dialysis) | FMS | Acute Kidney Injury; ESRD | completed | "NCT05339139 (SAfety of Regional Citrate Anticoagulation (SARCA Study)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-30 (ACTUAL); Lead Sponsor Fresenius Medical Care North America." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05339139)) |
| June 30, 2025 | [Casdozokitug primary completion](https://sec-api.dev/pdufa/casdozokitug) | CHRS | Hepatocellular Carcinoma | withdrawn | "NCT05359861 (Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-06-30 (ACTUAL); Lead Sponsor Coherus Oncology, Inc.; Results First Posted 2026-10-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05359861)) |
| June 30, 2025 | [Vanrafia® (atrasentan) primary completion](https://sec-api.dev/pdufa/atrasentan) | NVS | IgA Nephropathy; Immunoglobulin A Nephropathy | completed | "NCT05834738 (Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-30 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals; Results First Posted 2026-07-20." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05834738)) |
| June 2025 | [Anavex3-71 oral capsules primary completion](https://sec-api.dev/pdufa/anavex3-71-oral) | AVXL | Schizophrenia | delayed | "NCT06245213 (A Study of ANAVEX3-71 in Adults With Schizophrenia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-06-30 (ESTIMATED); Lead Sponsor Anavex Life Sciences Corp.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06245213)) |
| June 30, 2025 | [Efgartigimod iv primary completion](https://sec-api.dev/pdufa/efgartigimod-iv) | ARGX | Generalized Myasthenia Gravis; gMG; Myasthenia Gravis, Generalized | completed | "NCT06298552 (A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-06-30 (ACTUAL); Lead Sponsor argenx; Results First Posted 2026-08-10." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06298552)) |
| June 2025 | [HETLIOZ® (tasimelteon) primary completion](https://sec-api.dev/pdufa/tasimelteon) | VNDA | Sleep Wake Disorders; Sleep Disorders, Circadian Rhythm; Chronobiology Disorders | delayed | "NCT06701396 (Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2025-06-30 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06701396)) |

Other months: https://sec-api.dev/fda-calendar/2025-05 , https://sec-api.dev/fda-calendar/2025-07. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates June 2025: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2025-06

```bibtex
@misc{secapidev_fda_calendar_2025_06_20261116,
  title        = {PDUFA dates June 2025: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2025-06}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2025_06_20261116","title":"PDUFA dates June 2025: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2025-06","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
